Press release
Interstitial Lung Diseases Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs 2024
Explore our latest breakthroughs in Interstitial Lung Diseases Research. Learn more about our innovative pipeline today! @ Interstitial Lung Diseases Pipeline Outlook [https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Interstitial Lung Diseases Pipeline Report
* In November 2024:- Kinevant Sciences GmbH- A Randomized, Double-blind, Placebo-Controlled Phase 2 Study With Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects With Chronic Pulmonary Sarcoidosis. Participants will be randomized to receive namilumab or placebo in the 26-week Double-blind Treatment Period of the study. Namilumab, or placebo, will be administered subcutaneously (SC) every 4 weeks through Week 22 after the initial dosing period.
* In November 2024:- Boehringer Ingelheim- A Phase IIa/IIb, Randomised, Double Blind, Placebo-controlled, Parallel-group Dose-finding Study to Examine the Efficacy and Safety of BI 1839100 Administered Orally Over a 12-week Treatment Period in Patients With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis With Clinically Meaningful Cough.
* In November 2024:- Bristol-Myers Squibb- A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis. The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
* DelveInsight's Interstitial Lung Diseases pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for Interstitial Lung Diseases treatment.
* The leading Interstitial Lung Diseases Companies such as Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences, and others.
* Promising Interstitial Lung Diseases Therapies such as Dotarem, Belimumab, Nintedanib (Ofev Registered ), Anlotinib, BI 1015550, Abatacept, and others.
Stay informed about the cutting-edge advancements in Interstitial Lung Diseases Treatments. Download for updates and be a part of the revolution in cancer care @ Interstitial Lung Diseases Clinical Trials Assessment [https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Interstitial Lung Diseases Emerging Drugs Profile
* DWN12088: Daewoong Pharmaceutical
DWN12088 is an investigational therapy for idiopathic pulmonary fibrosis (IPF), that has shown the promising anti-fibrotic properties and appeared to be safe and well-tolerated in a recently-completed Phase I clinical trial that enrolled healthy volunteers. DWN12088 is an investigational IPF therapy that limits the body's ability to produce collagen by preventing an enzyme called glutamyl-prolyl-tRNA synthetase from adding proline to the protein's sequence. The FDA designated it as an orphan drug for idiopathic pulmonary fibrosis (IPF) in 2019. The drug is currently in Phase II stage of clinical trial evaluation to treat IPF.
* LYT-100: PureTech
LYT-100 is PureTech's most advanced wholly-owned therapeutic candidate. A deuterated form of pirfenidone, an approved anti-inflammatory and anti-fibrotic drug, LYT-100 is being advanced for the potential treatment of conditions involving inflammation and fibrosis, including lung disease (e.g., IPF and potentially other PF-ILDs and Long COVID respiratory complications and related sequelae), and disorders of lymphatic flow, such as lymphedema. PureTech completed a Phase 1 multiple ascending dose and food effect study evaluating LYT-100 in healthy volunteers and found it to be well-tolerated at all doses tested. PureTech is evaluating LYT-100 in a Phase 2 trial as a potential treatment for Long COVID respiratory complications and related sequelae as well as in a Phase 2a proof-of-concept study in patients with breast cancer-related, upper limb secondary lymphedema. PureTech is also advancing LYT-100 for the treatment of IPF and potentially other PF-ILDs and is planning registration-enabling studies. PureTech also expects to initiate a Phase 2 dose-ranging trial of LYT-100 in patients with IPF in the first half of 2022.
* BMS-986278: Bristol-Myers Squibb
BMS 986278, a lysophosphatidic acid receptor antagonist (LPA1) is being developed by Bristol-Myers Squibb, the treatment of idiopathic pulmonary fibrosis. BMS-986278 is a potent and complete antagonist of LPA action at LPA1-mediated Gi, Gq, G12, and -arrestin signaling pathways in both cells heterologously expressing human LPA1 and in primary human lung fibroblasts. Currently, it is in Phase II stage of clinical trial evaluation
Learn more about Interstitial Lung Diseases Drugs opportunities in our groundbreaking Interstitial Lung Diseases Research and development projects @ Interstitial Lung Diseases Unmet Needs [https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Interstitial Lung Diseases Companies
Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences, and others.
Interstitial Lung Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Intravenous
* Subcutaneous
Interstitial Lung Diseases Products have been categorized under various Molecule types such as
* Small molecule
* Cell Therapy
* Peptides
* Polymer
* Small molecule
* Gene therapy
Discover the latest advancements in Interstitial Lung Diseases Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Interstitial Lung Diseases Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Interstitial Lung Diseases Pipeline Report
* Coverage- Global
* Interstitial Lung Diseases Companies- Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences, and others.
* Interstitial Lung Diseases Therapies- Dotarem, Belimumab, Nintedanib (Ofev Registered ), Anlotinib, BI 1015550, Abatacept, and others.
* Interstitial Lung Diseases Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Interstitial Lung Diseases Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Interstitial Lung Diseases Pipeline on our website @ Interstitial Lung Diseases Drugs and Companies [https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Interstitial Lung Disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Interstitial Lung Disease- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* RO-0220912: Roche
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Daratumumab: Janssen Biotech
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* BGB 16673: BeiGene
* Drug profiles in the detailed report.....
* Preclinical Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Interstitial Lung Disease Key Companies
* Interstitial Lung Disease Key Products
* Interstitial Lung Disease- Unmet Needs
* Interstitial Lung Disease- Market Drivers and Barriers
* Interstitial Lung Disease- Future Perspectives and Conclusion
* Interstitial Lung Disease Analyst Views
* Interstitial Lung Disease Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=interstitial-lung-diseases-pipeline-therapeutics-assessment-companies-products-unmet-needs-2024]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Interstitial Lung Diseases Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs 2024 here
News-ID: 3718857 • Views: …
More Releases from ABNewswire
Total Joy Homecare Responds to Surging Demand for Senior Health Care Services in …
Total Joy Homecare expands services to meet growing Houston demand for in-home senior care, offering non-medical support that helps families maintain independence and dignity at home.
Houston's rapidly aging demographic has prompted local care provider Total Joy Homecare to expand its comprehensive support services, addressing the critical need for quality senior health care services [https://maps.app.goo.gl/hUcW1N7qWy5EdHJs5] throughout the Greater Houston area. The company's response comes as families increasingly seek reliable alternatives to…
Texas Company Introduces On-Site Carrier Repair Services to Reduce Fleet Downtim …
Texas Reefer Solutions introduces mobile carrier repair services in Dallas, revolutionizing how transportation fleets handle refrigeration breakdowns by providing on-site professional repairs, eliminating route deviations, and reducing cargo-threatening delays.
The transportation industry faces a significant challenge when refrigerated trucks require repairs, often forcing drivers to deviate from critical routes and schedules. Texas Reefer Solutions has emerged as a game-changing solution, introducing mobile carrier repair services [https://maps.app.goo.gl/P6nfg5WF7sckR7aZ8] that bring professional technicians directly…
Family Therapy in Birmingham: How the Right Therapist Can Transform Relationship …
Family therapy in Birmingham helps families improve communication, resolve conflict, and build stronger bonds. With the support of a qualified therapist near you, therapy creates a safe space to share, heal, and reconnect. Whether you're searching for therapy near me or counselling for your family, Phinity Therapy offers guidance for lasting change.
Families are the foundation of our lives. They provide love, support, and connection, but they can also be the…
Multiple Sclerosis Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Tri …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Multiple Sclerosis pipeline constitutes 75+ key companies continuously working towards developing 80+ Multiple Sclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Multiple Sclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
More Releases for Lung
Lung Cancer Prevalence Driving The Lung Cancer Drugs Market: Core Growth Enabler …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Lung Cancer Drugs Industry Market Size Be by 2025?
The market for lung cancer medications has seen a swift expansion in previous years. The market size is projected to escalate from $47.94 billion in 2024 to $54.13 billion in 2025, with a compound annual growth rate…
Lung Cancer Prevalence Driving The Lung Cancer Drugs Market: An Emerging Driver …
The Lending And Payments Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Lending And Payments Market?
The lending and payments market has experienced strong growth in recent years. It is set to rise from $12,326.44 billion in 2024 to…
Transforming the Lung Cancer Drugs Market in 2025: Lung Cancer Prevalence Drivin …
What Is the Expected Size and Growth Rate of the Lung Cancer Drugs Market?
The market size for lung cancer medications has seen swift expansion in the recent past. Its growth is projected to surge from $47.94 billion in 2024 to $54.13 billion in 2025, marking a compound annual growth rate (CAGR) of 12.9%. Factors contributing to the historical period's growth include epidemiology and demographics, regulatory authorizations, healthcare system infrastructure, and…
Transforming the Lung Cancer Drugs Market in 2025: Lung Cancer Prevalence Drivin …
What Is the Expected Size and Growth Rate of the Lung Cancer Drugs Market?
The market size for lung cancer medications has seen swift expansion in the recent past. Its growth is projected to surge from $47.94 billion in 2024 to $54.13 billion in 2025, marking a compound annual growth rate (CAGR) of 12.9%. Factors contributing to the historical period's growth include epidemiology and demographics, regulatory authorizations, healthcare system infrastructure, and…
Lung Cancer Screening Market - Empowering Proactive Lung Health: The Future of C …
Newark, New Castle, USA: The "Lung Cancer Screening Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Lung Cancer Screening Market: https://www.growthplusreports.com/report/lung-cancer-screening-market/7787
This latest report researches the industry structure,…
Artificial Lung Market May Set New Growth Story | Breethe, Lung Biotechnology, M …
A new research document is added in HTF MI database of 37 pages, titled as 'Artificial Lung - Medical Devices Pipeline Assessment, 2020' with detailed analysis, Competitive landscape, forecast and strategies. The study covers important players/vendors such as ALung Technologies Inc, Breethe, Inc., Case Western Reserve University, Lung Biotechnology PBC, MC3 Inc, McGowan Institute for Regenerative , Medicine, Miromatrix Medical Inc, The Charles Stark Draper Laboratory Inc, U.S. Ann Arbor…
